HEALTH● LOW1h ago · Oct 23, 2026, 7:27 PM
Genmab rises, Corcept falls on late-stage antibody-conjugate data for ovarian cancer
Seeking Alpha Tech · global
Genmab's stock has risen while Corcept's has fallen following the release of late-stage antibody-conjugate data concerning ovarian cancer. These market movements reflect the impact of the clinical trial results on the respective pharmaceutical companies.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH21m agoZamfara Govt Deploys Medical Personnel To Airport, Motor Parks For Ebola ScreeningChannels TVHEALTH28m agoMedicare Advantage plans cut for 1 million seniors, insurers sayCBS NewsHEALTH39m agoEbola Patient Showing Signs Of Recovery, Says FGChannels TVHEALTH48m agoBristol reports patient death in early trial of CAR-T therapy for multiple sclerosisSeeking Alpha Tech